Paclitaxel Injection, Solution
Product Images NDC 63323-763

14 FDA label images from Fresenius Kabi Usa, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Paclitaxel (NDC 63323-763). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Paclitaxel (Pac0h 0002 01)

Paclitaxel (Pac0h 0002 01)
Chemical structure of Paclitaxel, illustrating its complex multi-ring molecular arrangement with several functional groups, including esters and hydroxyls, consistent with the active ingredient in the 6 mg/mL formulation by Fresenius Kabi USA, LLC.*
FDA Label Image

Fig-1 (Pac0h 0002 02)

Fig-1 (Pac0h 0002 02)
A survival curve chart displaying the proportion of patients surviving over a period of 0 to 5 years. Two groups, labeled Cc and Tc, are compared with respective survival curves. The chart includes a table showing sample sizes, number of events, hazard ratio with confidence intervals, and the number of patients at risk at various time points.*
FDA Label Image

Fig2 (Pac0h 0002 03)

Fig2 (Pac0h 0002 03)
A survival curve chart titled "Figure 2. Survival: Cc Versus Tc (GOG-111)" comparing the proportion surviving over five years between two groups labeled Cc and Tc. The graph includes survival trajectories, risk numbers at various years, and a summary table with sample sizes, number of events, and hazard ratio with confidence interval.*
FDA Label Image

Paclitaxel-fig3 (Pac0h 0002 04)

Paclitaxel-fig3 (Pac0h 0002 04)
A line graph depicting disease-free survival over 4 years comparing two treatment groups labeled AC and AC+T. The y-axis represents the proportion disease free, ranging from 0 to 1, and the x-axis shows years from 0 to 4. The graph includes survival curves for AC and AC+T, with AC+T showing a higher disease-free proportion. An inset table displays sample sizes, number of events, hazard ratio (0.78), and 95% confidence interval for both groups. The number at risk is also shown for selected years.*
FDA Label Image

Paclitaxel-fig4 (Pac0h 0002 05)

Paclitaxel-fig4 (Pac0h 0002 05)
A survival curve chart comparing AC versus AC+T treatments over 4 years. The y-axis shows the proportion surviving, and the x-axis shows years. The chart includes the number of patients at risk and summary statistics including events, hazard ratio (HR), and confidence interval (CI) for both groups.*
FDA Label Image

Paclitaxel-fig5 (Pac0h 0002 06)

Paclitaxel-fig5 (Pac0h 0002 06)
A survival curve graph titled 'Disease-Free Survival - Receptor Status Negative/Unknown AC Versus AC+T,' showing proportion disease-free over a period of 4 years. It compares two groups, AC and AC+T, with AC+T demonstrating higher disease-free survival. The graph includes a table with sample sizes, number of events, hazard ratio with confidence interval, and numbers at risk over time.*
FDA Label Image

Paclitaxel-fig6 (Pac0h 0002 07)

Paclitaxel-fig6 (Pac0h 0002 07)
A line graph showing disease-free survival over a 4-year period comparing two groups: AC and AC+T treatments. The y-axis represents the proportion disease free, ranging from 0 to 1, and the x-axis shows time in years. The graph includes a table detailing the number of patients (N), number of events, and hazard ratio (HR) with 95% confidence intervals, plus a number-at-risk summary below the timeline for both groups.*
FDA Label Image

Paclitaxel-fig7 (Pac0h 0002 08)

Paclitaxel-fig7 (Pac0h 0002 08)
A Kaplan-Meier survival curve chart labeled 'Figure 7. Disease-Free Survival - Premenopausal AC Versus AC+T' comparing the proportion of disease-free patients over a 4-year period for two treatment groups, AC and AC+T. The chart includes a table of numerical data for number of subjects, events, hazard ratio with confidence interval, and number at risk at yearly intervals up to 4 years.*
FDA Label Image

Paclitaxel-fig8 (Pac0h 0002 09)

Paclitaxel-fig8 (Pac0h 0002 09)
A line graph titled 'Disease-Free Survival - Postmenopausal AC Versus AC+T' showing the proportion of patients disease-free over a period of 0 to 4 years. Two lines represent the groups AC and AC+T, with AC+T showing a higher proportion disease-free. The graph includes a table with event numbers and hazard ratio data, along with a count of patients at risk at different time points.*
FDA Label Image

Logo (Pac0h 0002 10)

FDA Label Image

Vial-100mg (Pac0h 0002 11)

Vial-100mg (Pac0h 0002 11)
Label for Paclitaxel Injection, USP (semisynthetic) 100 mg per 16.7 mL (6 mg per mL) by Fresenius Kabi USA, LLC. The label notes this multiple dose vial must be diluted prior to intravenous use and is a cytotoxic agent. Storage instructions specify to keep refrigerated between 20° to 25°C and to protect from light.*
FDA Label Image

Carton-100mg (Pac0h 0002 12)

Carton-100mg (Pac0h 0002 12)
Paclitaxel Injection USP 6 mg per mL (100 mg per 16.7 mL), semisynthetic, multiple dose vial packaging label. The box includes warnings about cytotoxicity, handling instructions, storage conditions at 20°C to 25°C, and dilution requirements for intravenous use. Labeler is Fresenius Kabi USA, LLC, with contact information and barcode shown.*
FDA Label Image

Vial-300mg (Pac0h 0002 13)

Vial-300mg (Pac0h 0002 13)
Paclitaxel injection, USP 300 mg per 50 mL (6 mg per mL) vial label from Fresenius Kabi USA, LLC. The label includes warnings to dilute prior to intravenous use and cautions that it is a cytotoxic agent. Storage instructions specify temperature range and protection from light. The vial is marked as multiple dose and prescription only.*
FDA Label Image

Carton-300mg (Pac0h 0002 14)

Carton-300mg (Pac0h 0002 14)
Paclitaxel Injection, USP 300 mg per 50 mL (6 mg per mL) carton label by Fresenius Kabi USA, LLC. The label highlights that the product is a cytotoxic agent requiring dilution prior to intravenous use, with storage instructions at 20°C to 25°C (68°F to 77°F) and protection from light. The carton also includes warnings to wear gloves when handling and notes this is a multiple dose vial. Bar code and contact information for Fresenius Kabi are present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.